Skip to content
Open access

Prognostic impact of microvascular dysfunction and systemic inflammation in women with chronic heart failure

Oct 2026 · European Heart Journal · 0 citations

TL;DR

The combined assessment of coronary microvascular function and inflammatory biomarkers independently predicts adverse outcomes and improves risk stratification beyond conventional markers and highlights the importance of the inflammation–microvascular axis in heart failure pathophysiology in women.

Abstract

Microvascular dysfunction and systemic inflammation are increasingly recognized as key contributors to chronic heart failure (CHF), particularly in women, who often present with preserved ejection fraction and cardiometabolic comorbidities. However, their combined prognostic significance remains insufficiently defined. This study evaluated the association between microvascular dysfunction, inflammatory biomarkers, and clinical outcomes in women with CHF. A prospective cohort study included 350 women with stable CHF (mean age 63.4 ± 10.7 years; 52% HFpEF, 31% HFmrEF, 17% HFrEF). Patients underwent echocardiography, 6-minute walk test (6MWT), and assessment of coronary microvascular function using coronary flow reserve (CFR) measured by Doppler echocardiography. Systemic inflammation was evaluated using high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and neutrophil-to-lymphocyte ratio (NLR). Microvascular dysfunction was defined as CFR <2.0. The primary endpoint was cardiovascular death or heart failure hospitalization during a median 20-month follow-up. Multivariable Cox regression, Kaplan–Meier analysis, and ROC curves were performed. Microvascular dysfunction was present in 162 patients (46.3%) and was associated with higher inflammatory markers (hs-CRP: 5.1 ± 2.3 vs 3.4 ± 1.8 mg/L; IL-6: 6.8 ± 2.5 vs 4.9 ± 2.1 pg/mL; NLR: 3.9 ± 1.6 vs 2.8 ± 1.2; all p < 0.001). CFR correlated inversely with IL-6 (r = −0.42, p < 0.001) and hs-CRP (r = −0.37, p < 0.001). During follow-up, the primary endpoint occurred in 104 patients (29.7%), with higher event rates in those with impaired CFR (41% vs 20%, log-rank p < 0.001). After adjustment for age, ejection fraction, NT-proBNP, diabetes, and renal function, independent predictors included CFR <2.0 (HR 1.92, 95% CI 1.32–2.79, p < 0.001), IL-6 (HR 1.36, p = 0.001), hs-CRP (HR 1.28, p = 0.006), and 6MWT distance (HR 0.81 per 50 m, p = 0.004). NT-proBNP showed weaker predictive value (HR 1.18, p = 0.04). A combined model integrating CFR and inflammatory biomarkers demonstrated superior prognostic discrimination compared with NT-proBNP alone (AUC 0.84 vs 0.71, p = 0.002), with significant net reclassification improvement (NRI 0.29, p = 0.01). Microvascular dysfunction is common in women with CHF and closely linked to systemic inflammation. The combined assessment of coronary microvascular function and inflammatory biomarkers independently predicts adverse outcomes and improves risk stratification beyond conventional markers. These findings highlight the importance of the inflammation–microvascular axis in heart failure pathophysiology in women and support targeted therapeutic strategies.

Read PDF

Similar papers

Open access Oct 2026

Systemic Inflammation and Adverse Heart Failure Outcomes

Background The association between systemic inflammation (SI) and outcomes among patients with heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF) is uncertain. Objectives This study aimed to evaluate the association between SI and clinical and economic outcomes among ind...

Alexander Sandhu, Adam Furst, A. Varshney et al. · 0 citations
Open access Oct 2026

Inflammatory profiling in ANOCA: IL-6 predicts cardiovascular events independent of coronary microvascular dysfunction

Women with angina and no obstructive coronary artery disease (ANOCA) remain at increased cardiovascular risk, likely in part driven by systemic inflammation and coronary microvascular dysfunction (CMD). Interleukin-6 (IL-6) is a key inflammatory mediator associated with cardiovascular events in the general popula...

R. Haahr, L. Rytoft, N. Mygind et al. · 0 citations
Open access Oct 2026

Statin treatment long-term prognostic impact and its association with immune-inflammatory biomarkers levels in acute heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) is characterized by diastolic dysfunction of left ventricle. There is evidence on the role of inflammation in the pathophysiology of HFpEF, however this knowledge is yet to be utilized in clinical practice. We conducted a study to evaluate the associat...

K. Stepien, P. Rostoff, A. Karcińska et al. · 0 citations
Open access Oct 2026

Clinical determinants of systemic inflammation in a real-world heart failure cohort

- Systemic inflammation plays a central role in cardiovascular disease and has been implicated in the pathophysiology of heart failure (HF). High-sensitivity C-reactive protein (hsCRP) represents an accessible marker of low-grade inflammatory activity; however, the clinical determinants of elevated hsCRP within h...

F. Psyllou, S. Bouloukou, D. Afendoulis et al. · 0 citations
Open access Sep 2026

Beyond Ejection Fraction: Inflammatory Risk and Mortality in Heart Failure

A higher systemic inflammatory burden was independently associated with recorded all-cause mortality across the spectrum of heart failure spectrum, and its incremental value appears modest.

B. Krastev, N. Spasova, D. Somleva et al. · 1 citation
Open access Oct 2026

Estimation Of Interleukin 6 Levels And Its Correlation With Severity Of Chronic Heart Failure

Background: Chronic heart failure is associated with persistent systemic inflammation, which contributes to ventricular dysfunction and disease progression. Interleukin-6 (IL-6) is a pro-inflammatory cytokine that may reflect the severity of myocardial impairment. Evaluating its relationship with clinical and echocardi...

Bhargav V. Bhat, S. Dr.Ashokavardhana, S. Dr.YashwanthN. et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.